MedTrace Logo

Pneumonia Vaccine Education Intervention Study

NCT06136832 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2025-07-08

No results posted yet for this study

Summary

The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine. The education intervention and subsequent option to get the vaccine will be done while the patient is admitted to inpatient care, prior to discharge. The main questions the study aims to answer are:

* Will supplemental education about the Prevnar 20 Pneumococcal vaccine influence patient acceptance rates when given a decision to receive it?
* Is there any other statistically relevant qualitative reasoning behind the patient's final decision for accepting or refusing the vaccine?

Conditions

  • Pneumonia, Pneumococcal
  • Vaccine

Interventions

BEHAVIORAL

Pneumococcal Vaccine Education

Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia

Sponsors & Collaborators

  • Geisinger Clinic

    lead OTHER

Principal Investigators

  • Jason Woloski, MD · Geisinger Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-06
Primary Completion
2025-01-26
Completion
2025-01-26

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06136832 on ClinicalTrials.gov